Canaccord Genuity Reiterates a 'Hold' on XOMA, Ltd. (XOMA); Strategy Shift a Move in Right Direction, but Awaiting More 052, Aceon Development Detail
Tweet
Share
E-mailGet Alerts XOMA Hot Sheet
Price: $40.17 --0%
Rating Summary:
4 Buy, 10 Hold, 0 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 8 | Down: 6 | New: 26
Rating Summary:
4 Buy, 10 Hold, 0 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 8 | Down: 6 | New: 26
Join SI Premium – FREE
Canaccord Genuity reiterates a 'Hold' on XOMA, Ltd. (NASDAQ: XOMA) price target of $2.00.
Analyst, Ritu Baral, said, "Reiterate rating and price target on XOMA on XOMA--052 (gevokizumab) potential in non--infectious uveitis and cardiovascular. Phase 2a and Phase 2b CRP reduction data suggest 052’s promise in CV. Early clinical data indicates 052’s potential benefit in Behcet’s uveitis, but final pivotal trial design will be critical for success."
Other highlighted points: 1) 052 Phase 3 expansion to non--infectious uveitis (NIU) may grow addressable US market 20x to 150k patients; 2) Cash burn about the same in 2012 despite restructuring; severe acne proof of concept (POC) data expected H2/12; and 3) Aceon deal with Servier has potential upside in fixed dose combo products.
For an analyst ratings summary and ratings history on XOMA, Ltd. click here. For more ratings news on XOMA, Ltd. click here.
Shares of XOMA, Ltd. closed at $1.66 yesterday.
Analyst, Ritu Baral, said, "Reiterate rating and price target on XOMA on XOMA--052 (gevokizumab) potential in non--infectious uveitis and cardiovascular. Phase 2a and Phase 2b CRP reduction data suggest 052’s promise in CV. Early clinical data indicates 052’s potential benefit in Behcet’s uveitis, but final pivotal trial design will be critical for success."
Other highlighted points: 1) 052 Phase 3 expansion to non--infectious uveitis (NIU) may grow addressable US market 20x to 150k patients; 2) Cash burn about the same in 2012 despite restructuring; severe acne proof of concept (POC) data expected H2/12; and 3) Aceon deal with Servier has potential upside in fixed dose combo products.
For an analyst ratings summary and ratings history on XOMA, Ltd. click here. For more ratings news on XOMA, Ltd. click here.
Shares of XOMA, Ltd. closed at $1.66 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Goldman Sachs Downgrades AAC Technologies Holdings Inc. (2018:HK) (AACAY) to Neutral
- Kotak Upgrades Narayana Hrudayalaya Ltd (NARH:IN) to Buy (1)
- HSBC Downgrades China Power International (2380:HK) (CPWIF) to Hold
Create E-mail Alert Related Categories
Analyst CommentsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
